Open Medicine Foundation ME/CFS Collaborative Center at CHU Sainte-Justine Archives - CanPath - Canadian Partnership for Tomorrow’s Health

CanPath – Canadian Partnership for Tomorrow’s Health Search

About Us
- Purpose, Vision & Mission
  CanPath is working in partnership to prevent disease and provide a platform for scientists to conduct innovative research.
- Our History
  The Canadian Partnership Against Cancer established the Canadian Partnership for Tomorrow Project (now CanPath) in June 2008.
- Leadership & Governance
  Meet the members of CanPath's Leadership Team, Operations Committee, National Strategic Advisory Council and more.
- National Coordinating Centre
  Meet the members of CanPath's operational core, based at the University of Toronto's Dalla Lana School of Public Health.
- Student Work and Opportunities
  Students are a cornerstone of our population health research program, driving innovation and discovery as the next generation of researchers and health professionals.
- Regional Cohorts
  Seven regional cohorts across ten provinces comprise CanPath's pan-Canadian partnership.
- Funders & Supporters
  Learn more about the partner organizations that provide funding and in-kind support to CanPath.
- Frequently Asked Questions
  Find out how CanPath will improve the health of Canadians and more.
- Contact us
  How to reach CanPath by phone, email, in-person, or make a data access request.
Research
- About the Study
  CanPath is Canada’s largest population health cohort and a gateway platform to data worldwide.
- Access Process
  The CanPath Access Portal provides researchers with the necessary resources to identify epidemiological and biological data available from participating cohorts to answer innovative research questions.
- Approved Projects & Studies
  CanPath has supported more than 100 research projects and activities, many of which have resulted in publications in high impact journals.
- Publications
  These publications are examples of research made possible with data from CanPath and its regional cohorts.
- Funding & Grant Opportunities
  Supporting researchers and innovators who are seeking financial backing and collaborative opportunities for their projects utilizing CanPath data
- COVID-19 Initiatives
  As Canada’s largest population health study, CanPath responded quickly to the pandemic by leveraging its existing infrastructure to support national COVID-19 research.
- CanPath Student Dataset
  The CanPath Student Dataset provides students with the unique opportunity to gain hands-on experience working with CanPath data.
- Collaborations
  The CanPath team is committed to collaborating with partners in order to enhance and accelerate research for a healthier Canada.
Participants
- About the Study
  CanPath is Canada’s largest population health cohort and a gateway platform to data worldwide.
- Participant Snapshot
  Understand the unique social, economic and health characteristics of CanPath participants and how this information is captured for research.
- Meet CanPath Participants
  Hundreds of thousands of Canadians have come together to be part of a study that reveals real breakthroughs.
- COVID-19 Antibody Study FAQ
  CanPath and its regional cohorts are conducting a COVID-19 antibody study of 20,000 participants across Canada.
News & Events
CanPath Access Portal

Newest to Oldest
Oldest to Newest

2023

Circulating microRNA expression signatures accurately discriminate myalgic encephalomyelitis from fibromyalgia and comorbid conditions

Authors: Evguenia Nepotchatykh, Iurie Caraus, Wesam Elremaly, Corinne Leveau, Mohamed Elbakry, Christian Godbout, Bita Rostami-Afshari, Diana Petre, Nasrin Khatami, Anita Franco, Alain Moreau

Researchers examined the levels of 11 specific molecules called miRNAs in individuals with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), fibromyalgia (FM), and those with both conditions (ME/CFS + FM), as well as in healthy controls. Using samples from 38 CARTaGENE participants and other sources, they found distinct patterns of these miRNAs that can help differentiate between ME/CFS, FM, and ME/CFS + FM, indicating that these miRNAs could serve as potential biomarkers to aid in the accurate diagnosis of these complex illnesses.

Read Publication